You are here

  • Home
  • Archive
  • Volume 81, Issue 6
  • Response to: ‘Changing the outcome measures, changing the results? The urgent need of a specific Disease Activity Score to adult-onset Still’s disease’ by Ruscitti et al

Article Text

Article menu

Download PDFPDF

Correspondence response
Response to: ‘Changing the outcome measures, changing the results? The urgent need of a specific Disease Activity Score to adult-onset Still’s disease’ by Ruscitti et al
Free
  1. Claudia Kedor1,
  2. Joachim Listing2,
  3. Jan Zernicke1,
  4. Eugen Feist1,3
  1. 1 Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany
  2. 2 Epidemiology Unit, Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany
  3. 3 Rheumatology, HELIOS Fachklinik Vogelsang/Gommern Klinik fur Rheumatologie, Gommern, Sachsen-Anhalt, Germany
  1. Correspondence to Claudia Kedor, Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin 10117, Germany; claudia.kedor{at}charite.de

https://doi.org/10.1136/annrheumdis-2020-218143

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We would like to thank Ruscitti et al 1 for their interest in our recent publication, in which we presented the results of the Canakinumab for treatment of adult onset Still‘s disease to achieve reduction ofarthritic manifestation (CONSIDER) trial. In this study, we investigated the efficacy of canakinumab for the treatment of patients with adult-onset Still’s disease (AOSD) with articular involvement (tender and swollen joint counts≥4 each) by means of a multicentre, double-blind, randomised, placebo-controlled trial.2 Patients were randomised to receive either canakinumab 4 mg/kg body weight (maximum 300 mg) every 4 weeks or placebo. According to the study goal, the primary endpoint was defined as the proportion of patients with a clinically relevant reduction in Disease Activity Score (DAS 28 >1.2) at week 12.

    Since no controlled studies existed in this indication at that time of the study initiation, we were not able to base our statistical considerations on known facts of response rates to placebo or any immunosuppressive regimen. After careful consideration, our sample size calculation indicated that it requires a total of n=68 randomised patients to show a significant difference between the …

    View Full Text

    Linked Articles